Navigation Links
MacuSight(TM) Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration
Date:2/25/2008

Sirolimus Demonstrates Favorable Safety Profile and Improvements in Visual

Acuity

UNION CITY, Calif., Feb. 25 /PRNewswire/ -- MacuSight(TM), Inc., a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, today announced positive preliminary data from a Phase 1 study of its lead product candidate in patients with wet (exudative) age-related macular edema (wet AMD). Similar to its Phase 1 study in patients with diabetic macular edema (DME), preliminary results from this prospective study of 30 patients demonstrated that MacuSight's proprietary formulation of sirolimus (rapamycin) was safe and well-tolerated in all doses tested with two different routes of administration. In addition, improvements in visual acuity consistent with anatomical retinal changes were observed following a single administration of sirolimus. These findings were presented at Bascom Palmer Eye Institute's Angiogenesis, Exudation and Degeneration 2008 conference by Pravin U. Dugel, M.D., member of MacuSight's scientific advisory board, managing partner, Retinal Consultants of Arizona, Phoenix AZ, clinical instructor, vitreoretinal diseases and surgery, department of ophthalmology, University of Arizona, and the study's lead investigator.

As part of the design of this randomized, open-label study, investigators evaluated the safety, tolerability and biological activity of sirolimus when delivered by either a subconjunctival or intravitreal injection. The trial showed no evidence of increased intraocular pressure, inflammatory response to treatment, or indication of progression of cataracts. Furthermore, the study provided an initial assessment of sirolimus' biological activity in AMD with patients demonstrating improvements in visual acuity despite extended duration of disease prior to entering the study. Additionally, patients also experienced anatomical improvements as demonstrated by a reduction in
'/>"/>

SOURCE MacuSight, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. MacuSight(TM) Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Macular Edema
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2008)...- Southern Research Institute,today announced that...ted,the organization to participate in the newly-f...Network (MLPCN). The MLPCN -- a collaborative,rese... Program which is,designed to benefit human health... and validate future targets for drug discovery., ...
(Date:9/4/2008)...umab to be Presented, PRINCETON, N.J., Sept. 4 /P...DX ) announced today that nine clinical abstracts ...ibody, in melanoma are scheduled to be,the subject...pean Society,for Medical Oncology (ESMO) being hel...following abstracts will include updated one-year ...
(Date:9/4/2008)...h Two Abstracts Accepted for Presentation, and...IDGEWATER, N.J., Sept. 4 /- Aegerion ...company focused on the treatment of,cardiovascular...tment of,Peter L. Garrambone, Jr. to the Company,s...ncludes more than 50 pharmaceutical,transactions e...
(Date:9/3/2008)...tCall/ -- Simcere,Pharmaceutical Group (NYSE: SCR... generic pharmaceuticals and manufacturer of the p...wn as Endostar) in China,announced the interim re...quest of the SFDA, Simcere initiated a Phase IV cl...erapeutic efficacy of Endu, a modified,version of ...
Breaking Medicine Technology:Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 2Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 3Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 4Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 2Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 3Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Workshop Helps Parents Kids Talk About Sex 23817 1Workshop Helps Parents Kids Talk About Sex 23817 2Non parental care of infants tied to unfavorable feeding practices 23813 1Non parental care of infants tied to unfavorable feeding practices 23813 2Non parental care of infants tied to unfavorable feeding practices 23813 3I Play Clean 28TM 29 and Old Spice Kick Off Campaign Challenging High School Students to Pledge Against Steroid Use 23809 1I Play Clean 28TM 29 and Old Spice Kick Off Campaign Challenging High School Students to Pledge Against Steroid Use 23809 2I Play Clean 28TM 29 and Old Spice Kick Off Campaign Challenging High School Students to Pledge Against Steroid Use 23809 3I Play Clean 28TM 29 and Old Spice Kick Off Campaign Challenging High School Students to Pledge Against Steroid Use 23809 4I Play Clean 28TM 29 and Old Spice Kick Off Campaign Challenging High School Students to Pledge Against Steroid Use 23809 5Chindex International Inc Announces CDC Contract Signing 23805 1Chindex International Inc Announces CDC Contract Signing 23805 2Chindex International Inc Announces CDC Contract Signing 23805 3Chindex International Inc Announces CDC Contract Signing 23805 4
...Calif.--(BUSINESS WIRE)--Apr 10, 2007 - The two mo...Fragile X and Down,syndromes, may share a common c...ity School of Medicine. The problem, a crippled,co...ciated with,autism., Although the genetics of the ...he brain seems to be the same, said Daniel Madison...
...(BUSINESS WIRE)--Apr 12, 2007 - INNOVIVE Pharmaceu...a from preclinical,studies of INNO-406, a potent o...vec-resistant or treatment-intolerant chronic,myel...n Association,for Cancer Research Annual Meeting. ...os Angeles Convention Center in Los Angeles,Calif...
Other Medicine Technology:Fragile X, Down Syndromes Linked to Faulty Brain Communication,Stanford Researcher Finds 2Fragile X, Down Syndromes Linked to Faulty Brain Communication,Stanford Researcher Finds 3Fragile X, Down Syndromes Linked to Faulty Brain Communication,Stanford Researcher Finds 4Innovive Pharmaceuticals Announces Additional Data Presentations at,American Association for Cancer Research Annual Meeting 2
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
...ents undergoing chemotherapy and radiation therapy...he study is also trying to investigate what can be...althy diet during treatment. Researchers at the U...cts of chemotherapy and radiation therapy on the s...
...Canada’s conjoined twins and to the public, who ha...d //after days of several tests that the twins are...nown by the names Krista and Tatiana Hogan came in...The twins, who are four months of age, portray dis...
...the quickest way to get from one floor to another....nding heart triggers anxiety or fear – possibly pr... Ellen W. Leen-Feldner, a University of Arkansas...nts who tend to respond fearfully to such common b...
...n is ninty-eight percent effective, offers a lower...rgery// for the treatment of varicoceles (varicose...n in men can cause pain, testicular atrophy or fer... life. “Varicoceles are a major, but underdiagnose...
Other Medicine News:Health News:Special Diets Necessary for Those Undergoing Chemotherapy 2Health News:Panic may Lead to Serious Mental Health Problems in Adolescents 2Health News:Nonsurgical Therapy Highly Effective for Pain and Infertility in Men 2
It provides cranial support in either prone or supine positions for premature infants and young children.
It provides cranial support in either supine or semi-sitting procedures.
The modular Doro headrest system is designed for both invasive and non-invasive applications in head and neck surgery. It can be adapted to all standard operating tables. It offers the decisive advan
Bunnel hand drill with Jacobs chuck, chuck size 4 mm.
Medicine Products: